WallStSmart

Eton Pharmaceuticals Inc (ETON)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 17786% more annual revenue ($14.30B vs $79.95M). ETON leads profitability with a -5.8% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

ETON

Hold

35

out of 100

Grade: F

Growth: 7.3Profit: 4.5Value: 5.0Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ETON2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
82.7%10/10

Revenue surging 82.7% year-over-year

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

ETON4 concerns · Avg: 2.3/10
Market CapQuality
$598.57M3/10

Smaller company, higher risk/reward

Price/BookValuation
24.6x2/10

Trading at 24.6x book value

Return on EquityProfitability
-18.2%2/10

ROE of -18.2% — below average capital efficiency

EPS GrowthGrowth
-12.6%2/10

Earnings declined 12.6%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ETON

The strongest argument for ETON centers on Revenue Growth, Operating Margin. Revenue growth of 82.7% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : ETON

The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ETON profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

ETON carries more volatility with a beta of 1.24 — expect wider price swings.

ETON is growing revenue faster at 82.7% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 35/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eton Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?